Roche posts data on SMA rival to drugs from Biogen, Novartis

Roche has presented data from a spinal muscular atrophy clinical trial it hopes will support an FDA approval of its challenger to drugs from Biogen and Novartis. The update adds figures to Roche’s earlier top-line readout but leaves questions about the competitiveness of risdiplam unanswered.